Ads
related to: hemophilia b treatment drugs names and photos list of medications- Acquired Hemophilia Info
View Efficacy And Safety Data For
Patients with Acquired Hemophilia.
- Pharmacology
View Mechanism Of Action Info
Including Video Resources.
- CFVIId Information
View Efficacy And Safety Data
For Patients with CFVIId.
- GT Information
View Efficacy And Safety Data
For Patients with GT.
- Clinical Data
View Information About Indications
Including Efficacy Data.
- Hospital Use
Clinical Pathway & Other Treatment
Information For Hospital Use.
- Acquired Hemophilia Info
Search results
Results From The WOW.Com Content Network
Strimvelis: treatment for adenosine deaminase deficiency (ADA-SCID) Talimogene laherparepvec (Imlygic): treatment for melanoma in patients who have recurring skin lesions [17] Tisagenlecleucel (Kymriah): treatment for B cell lymphoblastic leukemia [18] Valoctocogene roxaparvovec (Roctavian): treatment for hemophilia A [19] [20] [21]
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who are receiving routine prophylaxis and without pre-existing neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid detected by an FDA-approved test. [3] Inavolisib: Genentech
Hympavzi is the first and only anti-tissue factor pathway inhibitor (anti-TFPI) approved in the U.S. for hemophilia A or B and the first hemophilia medicine approved in the U.S. to be administered via
In the US, fidanacogene elaparvovec is indicated for the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who currently use factor IX prophylaxis therapy; or have current or historical life-threatening hemorrhage; or have repeated, serious spontaneous bleeding episodes; and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var ...
If approved, Pfizer's hemophilia A gene therapy will compete with BioMarin Pharmaceutical's one-time treatment Roctavian, which was approved in the U.S. last year and is priced at $2.9 million.
Ads
related to: hemophilia b treatment drugs names and photos list of medications